Topical application of a film‐forming emulgel dressing that controls the release of stratifin and acetylsalicylic acid and improves/prevents hypertrophic scarring

Wound Repair and Regeneration - Tập 21 Số 1 - Trang 55-65 - 2013
Elham Rahmani‐Neishaboor1, Reza Jallili2, Ryan Hartwell2, Victor C. M. Leung2, Nicholas Carr2, Aziz Ghahary2
1Department of Surgery/Division of Plastic Surgery, University of British Columbia, Vancouver, BC, Canada
2University of British Columbia Department of Surgery Division of Plastic Surgery Vancouver BC Canada

Tóm tắt

AbstractHere, we evaluate the efficacy of an emulgel dressing to control the release of an antifibrogenic factor, stratifin (SFN), along with an anti‐inflammatory drug, acetylsalicylic acid (ASA), to be used as a wound dressing with hypertrophic scar reducing features. Emulgel dressings were prepared by dispersing positively charged submicron vesicles in carboxymethyl cellulose gel. Release kinetics of SFN/ASA and toxicity for primary skin cells were assessed in vitro. Antifibrogenic efficacy of medicated emulgel dressings was tested on a rabbit ear fibrotic model. Following topical application on the wounds, emulgels formed an occlusive film and controlled the release of SFN and ASA for 7 and 24 hours, respectively. Wounds treated with SFN/ASA‐containing emulgel dressings showed an 80% reduction in scar elevation compared with untreated controls. Topical formulations were nontoxic for cultured human keratinocytes and fibroblasts. Inflammation was significantly controlled in treated wounds, as shown by a reduced number of infiltrated CD3+ T cells (p < 0.001) and macrophages. SFN/ASA‐treated wounds showed a significantly higher (p < 0.001) expression of matrix metalloproteinase‐1, resulting in reduced collagen deposition and less scarring. Film‐forming emulgel dressings that control the release of antifibrogenic and anti‐inflammatory factors provide an excellent treatment option for postburn hypertrophic scar management.

Từ khóa


Tài liệu tham khảo

10.1016/S0039-6109(05)70576-4

10.1371/journal.pmed.0040234

10.1111/j.1365-4632.2004.02570.x

10.4103/0378-6323.13777

10.1016/j.drudis.2008.08.009

10.1111/j.0022-202X.2004.22519.x

10.1002/jcb.20782

10.1111/j.0022-202X.2005.23765.x

10.1186/ar572

10.1002/path.1400

10.1074/jbc.274.31.21491

10.1097/00006534-199910000-00031

10.1056/NEJM199909023411006

10.1046/j.1524-475X.2003.11604.x

10.1111/j.1524-475X.2010.00598.x

10.1016/j.clindermatol.2008.05.004

10.2174/156720105774370267

10.1023/A:1015802427428

10.1016/S0168-3659(98)00156-4

10.1016/j.jconrel.2010.04.013

10.1080/02652040010000442

10.1016/j.jconrel.2004.08.008

10.4161/cbt.4.2.1472

10.1016/j.surg.2010.01.001

10.1016/j.ijpharm.2007.03.031

10.1186/1477-3155-6-8

10.1002/jbm.820210907

DiBiase MD, 1991, Investigations of epidermal growth factor in semisolid formulations, Pharm Acta Helv, 66, 165

10.1111/j.1524-475X.2009.00534.x

10.1097/00006534-199709000-00021

10.1007/s11095-009-9916-0

USP 24.Sterilization and sterility assurance. US Pharmacopeia.2001.

10.1016/j.bjps.2008.03.022

10.1111/j.1067-1927.2004.0abstractxp.x

10.1111/j.1524-475X.2008.00404.x

Escobar‐Chavez JJ, 2006, Applications of thermo‐reversible pluronic F‐127 gels in pharmaceutical formulations, J Pharm Pharm Sci, 9, 339

10.12968/jowc.2003.12.4.26484

10.1111/j.0022-202X.2004.23521.x

10.1111/j.1524-475X.2007.00224.x

10.1016/S0305-4179(97)00070-3

Thông tin
Thông tin xuất bản

Wound Repair and Regeneration

Tập 21 Số 1

55-65

Thông tin tác giả